Stock DRMA DERMATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Dermata Therapeutics, Inc.

Equities

DRMA

US2498454055

Delayed Nasdaq
Other stock markets
 03:28:54 2024-05-23 pm EDT 		5-day change 1st Jan Change
3.25 USD -10.22% Intraday chart for Dermata Therapeutics, Inc. -37.50% -64.48%
Mar. 21 Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 05 Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market under Nasdaq Rules
AQ
Dermata Therapeutics : Provides Corporate Update and Reports First Quarter 2024 Financial Results - Form 8-K
PU
Dermata Therapeutics : Provides Corporate Update and Reports Full Year 2023 Financial Results - Form 8-K
PU
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Dermata to Present at the Emerging Growth Conference on February 7, 2024
AQ
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected
MT
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket
MT
Top Premarket Gainers
MT
North American Morning Briefing : Bond Yields Rise Again as Jobs Data Loom
DJ
Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
CI
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
AQ
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon
MT
Dermata Therapeutics to Begin Enrolling Patients in Acne Drug Study; To Raise $2.3 Million
MT
Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols
CI
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Dermata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne
CI
Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis
CI
Dermata Therapeutics Completes $1.8 Million Share Offering
MT
DERMATA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DRMA Stock
  4. News Dermata Therapeutics, Inc.